🔎 Trials Near Me

Akèy › Maladi fwa steatotik › Lwizyàn › New Orleans

Etid klinik pou Maladi fwa steatotik nan New Orleans, LA

8 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan ak bò kote New Orleans (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Ap rekriteFaz 3
  • 89bio Clinical Study Site, Marrero · 4 mi lwen
Laj 18 a 80 · Tout sèks · Mizajou Oct 5, 2026 · NCT06318169

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Ap rekriteFaz 3
  • Tandem Clinical Research, Marrero · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Ap rekriteFaz 3
  • Akero Clinical Study Site, Marrero · 4 mi lwen
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Ap rekriteFaz 3
  • GSK Investigational Site, Marrero · 4 mi lwen
Laj 18 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT07221188

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

Ap rekriteFaz 2
  • GSK Investigational Site, Marrero · 4 mi lwen
Laj 18 a 70 · Tout sèks · Mizajou Aug 3, 2026 · NCT06613698

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Ap rekriteFaz 3
  • GSK Investigational Site, Marrero · 4 mi lwen
Laj 18 a 75 · Tout sèks · Mizajou Jul 27, 2026 · NCT07221227

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Ap rekriteFaz 1/2Volontè an sante akeyi
  • Tandem Clinical Research, Marrero · 4 mi lwen
Laj 18 a 75 · Tout sèks · Mizajou Apr 16, 2026 · NCT05648214

Etid Maladi fwa steatotik nan lòt vil

Lòt etid nan New Orleans

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.